To improve the results of high-dose therapy with autologous stem cell transplantation, new conditioning regimens with acceptable toxicity must be developed. The aim of this study was to evaluate the feasibility and toxicity of two myeloablative regimens performed at a 2-month interval. After salvage chemotherapy and collection of peripheral stem cell progenitors (median CD34 ؉ cells/kg: 11 ؋ 10 6 /kg), (n ‫؍‬ 15) patients with aggressive non-Hodgkin's lymphoma with poor prognostic factors or refractory Hodgkin's disease (n ‫؍‬ 9) received intensified regimens. The first conditioning regimen, consisting of BCNU-cyclophosphamide-VP16-mitoxantrone was followed by transplantation of a median number of 4 ؋ 10 6 CD34 ؉ cells/kg; then, after a median interval of 56 days, a second preparative regimen, combining busulfan-aracytine-melphalan or TBI ؉ aracytine-melphalan, was followed by transplantation of a median of 4 ؋ 10 6 CD34 ؉ cells/kg. After regimens 1 and 2, respectively: median time to neutrophil recovery Ͼ500/l was 11 days (both times); median time to platelet counts Ͼ50 000/l was 14 and 36 days, but values Ͼ20 000/l were reached by days 13 and 16 (P ‫؍‬ 0.9); mucositis grade III-IV was observed in 11 and 15 cases. The median number of days with fever Ͼ38؇C was significantly higher (7.8 days) after the second transplant (P Ͻ0.05). Three cases of veno-occlusive disease (VOD) were observed after the second transplant. At a median follow-up of 18 months, 14/24 (58%) patients remained in CR, seven patients had died (two of VOD and five after relapse) and two were alive in relapse. These results indicate that tandem transplants performed at a 2-month interval in poor risk lymphoma can be used with acceptable hematotoxicity. VOD remains the major drawback and hepatotoxic drugs, such as busulfan, should be used with caution. Longer term followup of a larger cohort of patients is needed to ascertain the overall efficacy. Keywords: tandem transplants; Hodgkin's disease; nonHodgkin's lymphoma; veno-occlusive disease Conventional-dose anthracycline-containing chemotherapy associated with radiotherapy has now been well documented to result in long-term disease-free survival in 60-70% of the patients with advanced Hodgkin's disease (HD) 1 and 45-50% of those with unselected aggressive non-Hodgkin's lymphoma (NHL).
Conventional-dose anthracycline-containing chemotherapy associated with radiotherapy has now been well documented to result in long-term disease-free survival in 60-70% of the patients with advanced Hodgkin's disease (HD) 1 and 45-50% of those with unselected aggressive non-Hodgkin's lymphoma (NHL). 2 For NHL patients, prognosis is determined based on the clinical characteristics defined by the International Prognostic Index (IPI), 3 with the survival rate for patients with 0-2 adverse factors ranging from 80 to 60%. However, for patients with Ͼ2 adverse prognostic factors actuarial survival is inferior to 40% and for those with primary refractory disease who fail to achieve complete remission (CR) after standard chemotherapy, the prognosis is poor with conventional salvage chemotherapy. 4 The most promising approach for these very poorrisk patients is the use of high-dose therapy (HDT) followed by autologous stem cell transplant (ASCT). Prospective trials have shown HDT ϩ ASCT to be superior to chemotherapy at conventional doses for the treatment of both sensitive relapse of intermediate-high grade NHL 5 and as initial treatment for aggressive B cell lymphoma with at least two adverse prognostic factors. 6, 7, 8 For HD patients, the long-term outcome after a first relapse remains poor, especially for those with a time from primary treatment failure Ͻ12 months. 9, 10 The role of HDT ϩ ASCT has been widely investigated in patients with refractory or relapsing HD with progression-free survival ranging from 30 to 60% at 3 years. 11 Several prognostic factors (time to relapse inferior to 1 year, disseminated relapse, number of lines of treatment) have been described to better characterize the group of refractory or relapsing patients who can be salvaged with HDT. The initial chemosensitivity to salvage chemotherapy remained the most important prognostic factor. [10] [11] [12] The proportion of patients salvaged by HDT ϩ ASCT reached 45-60% in patients with good prognostic features according to the prognostic model proposed by Vose et al 13 for NHL patients and by Brice et al 14 for those with HD. However, for patients with adverse prognostic factors, the probability of being cured decreases rapidly to under 40% with standard conditioning regimen and ASCT. More effective treatments are needed to increase the cure rate for patients with relapsed NHL and HD. These relapses are likely attributable to persistent residual disease which was not eradicated by the standard conditioning regimen. One way of improving preparative regimens is to use multiple or tandem transplants. There have been encouraging and promising results in patients with multiple myeloma with total therapy (high-dose melphalan and total body irradiation (TBI), consisting of two ASCT performed at a 3-month intervals). 15 The same type of approach has been developed for breast carcinoma with the use of cyclic, however not truly myeloablative HDT. 16, 17 The report from the European Bone Marrow Transplant (EBMT) study showed, in a limited number of patients, the feasibility of a second transplant in relapsed HD and high-grade NHL with adverse factors. 18 Based on these observations, 24 patients, 15 with poor-prognosis NHL (two or three adverse factors, relapse Ͻ1 year after primary treatment or refractory disease) and nine HD patients with refractory or recurrent disease (Ͻ1 year) after first-line therapy were subjected to a tandem-transplant program with ASCT including two intensive preparative regimens. The initial regimen of BCNU-cyclophosphamide-VP16-mitoxantrone (BCVMxt) 9 was followed by a second regimen consisting of busulfan or TBI and a combination regimen. The aim of this study was to evaluate the feasibility and toxicity of two successive myeloablative treatments, in a short-time interval (Ͻ2 months), followed by ASCT in patients with NHL or HD with defined adverse prognostic factors for standard ASCT.
Patients and methods

Patient characteristics
Between August 1994 and December 1997, 24 patients with advanced lymphoma, HD or NHL, received double HDT at the Hospital Saint-Louis. For the purpose of the study, diagnosis and indications were classified into two groups: first intention and relapse. Patients with high-grade NHL with at least two adverse prognostic factors according to the IPI were transplanted as first-line therapy after cytoreductive chemotherapy. Relapsing NHL and HD patients had to have at least one adverse prognostic factor: end-of-treatment to relapse interval Ͻ1 year. Other eligibility criteria were: Ͻ65 years of age before transplant; life expectancy of at least 12 weeks; absence of active infection; and the following organ function criteria: left ventricular ejection fraction (LVEF) у45%, and DL CO у50%, bilirubin Ͻ2 mg/dl and creatinine Ͻ1.5 mg/dl. Patients with active central nervous system involvement or those who were HIV-positive were not eligible. Full staging was performed for each patient including: physical examination, biological parameters and imaging studies with at least a thoracoabdominal computed tomography (CT) scan and bone marrow (BM) biopsy. Patients participated in on-going trials and gave their informed consent according to hospital regulations. Patient characteristics are summarized in Table 1 . The median age was 35 years (range: 18-57) with 14 patients Ͻ40 years old. The M/F sex-ratio was 2. Fifteen patients had a diffuse large B cell NHL and nine HD (eight type 2 nodular sclerosis and one type 3 mixed cellularity) in this study.
Nine NHL patients with a median age of 42 years (range: 24-54 years) were transplanted as part of their initial therapy. Fifteen relapsing patients (nine HD and six NHL) with a median age of 33 years (range: 18-52 years) were treated with this protocol. All nine HD patients had an interval to relapse Ͻ1 year and one of them also had an extra-nodal relapse.
Treatment
The first-line treatments and conditioning regimens are reported in Table 2 
Tumor response criteria
A complete clinical response (CR) was defined as the disappearance of all sites of disease including normal bone marrow in the case of initial involvement. A partial response (PR) was defined as у50% reduction in the bidimensional measurements of each measurable lesion. Patients who could not achieve CR because of persistent small masses were considered to be good partial responders (GPR). Stable disease (SD) was defined as a reduction of Ͻ50% in these measurements. The remaining patients were considered to be failures. Tumor mass was assessed at diagnosis, relapse, before the first and second transplants, and 3 months after ASCT with clinical examination and imaging studies (CT scan or nuclear magnetic resonance), and BM biopsy in the case of initial involvement. Relapsing patients responding after the salvage chemotherapy regimen were considered to have chemosensitive relapses. Clinical restaging was carried out at 3-month intervals during the first 2 years of follow-up with full restaging yearly or in the case of new symptoms.
Stem cell collection
Peripheral blood progenitor cells (PBPC) were collected by leukaphereses during the hematological recovery phase after mobilizing chemotherapy and G-CSF. Chemotherapy regimens were heterogeneous, consisting of either the last cycle of induction treatment, or they included high-dose cyclophosphamide (2-7 g/m 2 ). Twenty-four patients received G-CSF (5 g/kg/day) from day 5 after chemotherapy until the last leukapheresis. Peripheral blood CD34 ϩ cell counts were determined daily and leukaphereses were started when they were Ͼ20/l. Leukaphereses were performed with continuous flow blood cell separators. The minimum number of CD34 ϩ cells required for two transplants was 6 ϫ 10 6 /kg. If the number of CD34 ϩ cells 749 
UPN ϭ unique patient number; NHL ϭ non-Hodgkin's lymphoma; HD ϭ Hodgkin's disease; BM ϭ bone marrow; LDH ϭ lactate deshydrogenase; DLCL ϭ diffuse large-cell lymphoma; NS ϭ nodular sclerosis HD; MC ϭ mixed cellularity HD; N ϭ normal; A ϭ abnormal.
was insufficient after three leukaphereses, G-CSF treatment (10 g/kg/day) was given at steady state for 5 consecutive days, and collection was attempted on day 4-5. BM was not collected from any patient.
HDT and transplantation modalities
After documentation of maximum response and complete hematological recovery after induction chemotherapy, patients were admitted to the hospital for ASCT.
First transplant:
The conditioning regimen for 20 patients was BCV-mitoxantrone (Mxt) (BCNU (carmustine) 300 mg/m 2 i.v. once daily on day Ϫ4; cyclophosphamide 1500 mg/m 2 once daily i.v. for 4 consecutive days from day Ϫ7 to day Ϫ4 (total dose 6000 mg/m 2 ); VP16 250 mg/m 2 i.v. once for 4 consecutive days from day Ϫ7 to day Ϫ4; Mxt 45 or 30 mg/m 2 i.v. once on day Ϫ8). Three patients received BCV without Mxt because of cardiac dysfunction and one patient received BEAC with the addition of aracytine 100 mg/m 2 twice daily i.v. for 4 consecutive days from day Ϫ7 to day Ϫ4, for a total eight doses. After this first conditioning regimen, half of the stored PBPC were thawed at the bedside and immediately infused i.v.
Second transplant:
The second transplantation was done 45 to 60 days after the first reinjection (median: 56 days). Different regimens were used: busulfan-carboplatin-melphalan (BCM) or TBI-carboplatine-melphalan (TCM) in 19 patients (busulfan 3 mg/kg p.o. in divided doses daily for 4 days (total 12 mg/kg) for 4 days from day Ϫ6 to day Ϫ3; carboplatin 400 mg/m 2 i.v. once daily from day Ϫ5 to day Ϫ3; melphalan, 140 mg/m 2 i.v. once on day Ϫ2). The busulfan dose was decreased in four patients (three received 10 mg/kg and one patient 8 mg/kg) with risk factors for veno-occlusive disease (VOD). TBI delivered 12 Gy in six fractions and 3 days, the lung dose being limited to 9 Gy by partial shielding and was combined with the same doses of carboplatin and melphalan for eight patients. The second regimen combined busulfan (12 mg/kg p.o.), aracytine (100 mg/m 2 twice daily i.v. for 4 consecutive days from day Ϫ6 to day Ϫ3) and melphalan (140 mg/m 2 i.v. on day Ϫ2) (BAM) or TBI, aracytine and melphalan (TAM) for five patients. Infusion of the remaining half of PBPC was done after preparative regimen. Thus, the second high-dose regimen for 11 patients included TBI and that for 13 patients included busulfan as described above. The HDT regimens are summarized in Table 2 .
Post-intensification therapy: After recovery from both HDT regimens, five patients underwent radiation therapy to sites of prior bulky disease.
Supportive care
All patients had an indwelling central venous catheter and were housed in laminar air-flow rooms; they received 
BCV-Mxt ϭ BCNU-cyclophosphamide-vindesine-mitoxantrone; ACVBP ϭ Adriamycin-cyclophosphamide-VP16-bleomycin-prednisone; BEAC ϭ BCNU-VP16-aracytine-cyclophosphamide; BEAM ϭ BCNU-etoposide-cytarabine-melphalan; IVA 75 ϭ ifosfamide-VP16-adriamycin; BCM ϭ busulfancarboplatine-melphalan; TCM ϭ TBI (total body irradiation)-carboplatine-melphalan; TAM ϭ TBI-aracytine-melphalan; BAM ϭ busulfan-aracytinemelphalan; RT ϭ localized radiotherapy; EBCP-MV ϭ epirubicin-bleomycin-cyclophosphamide-prednisone-mechlorethamine-velbe; MOPP/ABV ϭ mechlorethamine-vincristine-procarbazine-prednisone/adriamycin-bleomycin-vinblastine; ADR ϭ adriamycin; MIVE ϭ Mitoxantrone-ifosfamide-VP16; DHAP ϭ dexamethasone-aracytine-cisplatine; CHOP ϭ cyclophosphamide-doxorubincin-vincristine-prednisone; CY ϭ cyclophosphamide; ESHAP ϭ etoposide-methylprednisolone-high-dose aracytine-cisplatine; MINE-R ϭ Mitoxantrone-ifosfamide-navelbine; CR ϭ complete response; GPR ϭ good partial response; SD ϭ stable disease; VOD ϭ veno-occlusive disease.
prophylactic oral antibiotics for gut decontamination. Prophylactic anti-fungal and anti-viral treatments were administered i.v. For fever Ͼ38.5°C, three blood cultures were taken and the empirical broad spectrum antibiotics were prescribed G-CSF (5 g/kg/day i.v. over 1 h) was begun 24 h after infusion of stem cells and continued until an ANC Ͼ1000/l was obtained. All patients received irradiated blood and platelet products when the hemoglobin was Ͻ8 g/dl and platelet count Ͻ20 000/l. Heparin (1 mg/kg) was administered i.v. to two patients over 24 h to prevent VOD during the first intensification and to 13 patients during the second.
Toxicity evaluation criteria
Toxicity was scored according to the criteria of Bearman et al 2 and was defined as severe (grade III) or life-threatening (grade IV).
Before conditioning treatment, cardiac and pulmonary functions were evaluated by isotopic left LVEF and pulmonary function tests. These tests were repeated 1 month after the first intensification and 3 months after the second. Factor VII and protein C levels were determined before conditioning (day Ϫ8), the day of ASCT (day 0) and weekly (days 7, 14 and 21). VOD was diagnosed on the basis of clinical criteria with at least two of the following features present: jaundice (bilirubin у2 mg/dl), tender hepatomegaly and/or unexplained weight gain (Ͼ5% from baseline).
Statistics
The time to hematological reconstitution was measured from the day of PBPC to the day when an absolute neutrophil count (ANC) Ͼ500/l was seen, with transfusion independence for platelets (Ͼ20 000/l) and red blood cells (hematocrit level Ͼ25%). Times to hematological recovery were compared using the chi-square test with the Fisher's exact test 22 and survival data were calculated from the day of first ASCT. The Mann-Whitney U test was used to assess the effect of quantitative factors on the rates of response and toxic effects. 23 Survival curves were estimated using the Kaplan-Meier method. 24 
Results
Response to initial treatment
For the nine patients subjected to tandem transplants as first-line therapy, the debulking treatment comprised four cycles of ACVBP and led to CR for two patients and GPR for seven patients. Among the 15 patients in relapse, 13 were chemosensitive (CR ϭ 3, GPR ϭ 10) and two were chemorefractory after the second-line therapy.
Response to the tandem transplants
Eight of the nine patients were considered to be in CR after the first transplant in the first-line group and nine of 15 patients in relapse group (NHL ϭ 5; HD ϭ 4). On day 100 after completion of the second transplantation procedure, six of nine were in CR in the first-line group and 10/15 (NHL ϭ 3; HD ϭ 7) in the relapse group. Thus, the response rate was 16/24 (67%) with one death due to VOD on day 35 and six patients considered to be in relapse.
Five patients (NHL ϭ 2; HD ϭ 3) received between 20 and 30 Gy to initial bulky localizations or residual mass 1 month after the second regimen without any toxic effect. None of these patients had received TBI during the conditioning regimen for the second transplant.
Stem cell collection and reinfusion
The number of hematological PBPC was evaluated as CD34 ϩ cells. The median number of leukaphereses was 2.29 (range: 1-6) providing a median collection of 11.04 ϫ 10 6 CD34 ϩ cells/kg (range: 5.21-37.52). The median numbers of CD34 ϩ cells/kg infused for the first and second ASCT, respectively, were 4.78 ϫ 10 6 (range: 1.83-17.5) and 4.88 ϫ 10 6 (range: 2.31-19.9) and were not statistically different. Two patients required treatment with G-CSF (10 g/kg/day) for 5 consecutive days for improving PBPC collection and for two others, a second collection was successfully carried out after the first intensification (5.83 and 2.6 ϫ 10 6 CD34 ϩ cells/kg). /l were comparable after the first and second intensifications, respectively 11.6 days (range: 9-20) and 11.1 days (range: 9-17). The respective median times to reach a platelet count Ͼ50 ϫ 10 9 /l were 14.8 days (range: 9-22) and 36.2 days (range: 11-120) (P ϭ 0.0001). Three months after the second transplant, seven (29.2%) patients were still transfusion-dependent (five for platelets, one for RBC and one for both). Thus, after the second intensive regimen, the median time to reach a platelet count у100 000 ϫ 10 9 /l was 52 days (range: 11-130 days) for the 23 patients alive 2 months after the second round.
Hematological recovery
Toxicity
The main extrahematological toxicities are summarized in Table 4 . All patients developed neutropenic fever during both HDT. The median number of febrile days was significantly lower during the first ASCT than the second one (3.29 vs 7.82; P ϭ 0.0001). During the first HDT, three patients had documented infections (two Staphylococcus and one Klebsiellae) and seven during the second intensification (three Staphylococcus, two Streptococcus, one Anaerobic bacterium and one cytomegalovirus infection). All fever and/or infections were managed successfully with broad-spectrum antibiotics. No deaths or major morbidity were attributed to infectious causes.
Three patients (one patient during the first HDT and two during the second one) developed grade III or IV hemorrhagic cystitis, which was reversible in all but one patient who required bladder irrigation, electrocoagulation twice and transfusion of more than 70 platelet units. Grade III-IV mucositis, requiring morphine, occurred in 11 patients (46%) during the first HDT and 15 (63%) during the second intensification and was not statistically significant (P ϭ 0.38).
Veno-occlusive disease
Three patients with NHL developed liver biopsy-confirmed VOD according to the Seattle criteria 25 after the second ASCT (one patient with TBI and two patients with busulfan in the conditioning regimen). Patient 4 died on day 35 after the second ASCT and patient 10 on day 330. The latter was treated with vincristine (1 mg) every 2 weeks for a medullary relapse. Patient 15 received rh-tPA (Actilyse, Boehringer, Mannheim, Germany; 10 mg/day i.v. for 4 days from days 10 to 14) and showed clinical and biological improvement 10 days after the histological diagnosis. Portal hypertension had resolved 1 year after the end of second HDT. For all these patients, factor VII and protein C levels were within the normal range before treatment, were decreased on day 7 after the first ASCT with mean values of 60% (range: 31-80) and 85% (range: 55-140), respectively, during the first transplant and then returned to normal. During the second ASCT, these three patients experienced comparable decreases with mean values for factor VII and protein C on day 7 after transplant of 56% (range: 42-75) and 57% (range: 37-93), respectively, associated with severe clinical VOD.
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Hospital stay
The duration of hospitalization was defined as the number of days in the hospital from the beginning of the conditioning regimens to the last day in hospital after ASCT. There was no difference between the duration of hospital stay for the first and the second procedure (P ϭ 0.64) ( Table 4) .
Follow-up
With the median follow-up at about 18 months (range: 4-36), 14 patients remain in continuous complete remission (CCR), seven patients have died (two of VOD and five after relapse) and two patients are alive with disease in relapse. For the 14 patients in CR, six patients are in the first-line therapy group and eight in the salvage group (NHL ϭ three patients; HD ϭ five patients). The overall survival (OS) is shown in Figure 1 . There was no difference between HD and NHL patients.
Toxicity after day 100
The most important toxicity that occurred after ASCT was a decline in performance status. Three months after the second procedure, seven of 22 (32%) patients had lost 5% of their initial weight and five of 22 (23%) Ͼ5%. The major problems after leaving the hospital were persistent gastrointestinal toxicity including anorexia, nausea, vomiting or diarrhea (36%) and eight patients were hospitalized because of such symptoms. There was one clinically evident cardiac toxicity during ; mediastinal irradiation: 40 Gy) with a normal pretreatment LVEF (58%) developed congestive heart failure requiring digoxin and a diuretic for 9 months until she relapsed and died 3 months later. No other patient developed cardiac failure and the cardiac nuclear-gated angiographies done before ASCT and 3 months after were stable: mean LVEF value of 61.09% (range: 42-72%) and 61.08% (range: 50-77%), respectively.
Seven patients developed an infection during the first year after the tandem transplants (one Mycobacterium tuberculosis, one Pneumocystis carinii, three herpes zoster infections, one systemic Candida infection and one pulmonary infection). All these infections were successfully treated.
Discussion
The place of HDT with ASCT support has been well established over the past years in a number of selected hematological malignancies. [4] [5] [6] [7] [8] The Parma study showed that for patients with relapsed NHL, ABMT was superior to chemotherapy for overall survival and event-free survival. Unfor-tunately, patients with primary refractory or resistant disease rarely achieve CR post transplantation. Chemosensitivity of the tumor after salvage chemotherapy is the main factor predicting outcome for patients who relapse after conventional chemotherapy. HDT might be better if attempted earlier, 4, 7 before the disease becomes chemoresistant in patients with several adverse prognostic factors. Vandenberghe et al 18 showed that a second transplant might be beneficial, using registry data on 34 patients with HD or NHL who had relapsed after one myeloablative treatment transplant protocol. Among them, four patients received, as planned, tandem transplants. More precisely, concerning relapsing or refractory HD patients, Ahmed et al 26 showed that progression-free survival of the refractory patients who could tolerate a second procedure was similar to that of patients with sensitive disease (median survival: 45 months with a median follow-up of 4 years). Currently, little information has been published concerning procedure-related morbidity or NHL outcome after tandem or second transplants and available data are mostly from patients with solid tumors or myeloma. [15] [16] [17] [27] [28] [29] [30] The most difficult problems are to individualize a poor prognosis group of patients who can benefit from tandem transplants and to find two myeloablative conditioning regimens with acceptable toxicities. The purpose of this study was to determine the different toxicities encountered in tandem transplants performed in poor prognosis lymphoma; early and late hematological recoveries, extra-hematological toxicities and to assess failure-free survival in this population. The 24 patients included in this feasibility study had several adverse prognostic factors and were considered to have a poor prognosis even for salvage treatment with standard ASCT. The expected probability of survival with one standard conditioning regimen had to be inferior to 40% to be included in this study. Thus, for the relapse group, inclusion criteria were: refractory disease or end-of-treatment to relapse interval Ͻ1 year. 13, 14, 31 In addition, nine patients with aggressive lymphoma with at least two adverse prognostic factors according to the IPI, received this tandem protocol as first-line therapy after debulking chemotherapy with ACVBP induction. 7 In this group of patients, the remission rate is only 65% and tandem high-dose procedures may have a role in treatment strategies to improve the response rate and consolidation. Regimen-related toxicity (RRT) is one of the major barriers to the successful outcome of ASCT. 21 Since the development of PBPC, the main lethal toxicity has been extrahematological. In our study, VOD was the main cause of RRT and was responsible for two deaths. Its incidence varies from 2 to 50% in reported series, depending on patients and type of graft. 25 VOD is more often seen during allogeneic transplantation. The mortality rate, depending on the severity of the symptoms, varies from 20 to 50% and our ability to predict which individual patients will develop life-threatening VOD, using pretransplant characteristics, is poor. 32, 33 The other toxicities were mainly hematological and gastrointestinal. The rapid hematological engraftment of neutrophils was associated with acceptable hematological toxicity and similar durations of hospital stay for both procedures. With mobilized PBPC and G-CSF, it was possible to complete two HDT in a time interval shorter than Ͻ3 months. However, platelet recovery in six patients was delayed after the second transplant until day 100 despite infusion of Ͼ5 ϫ 10 6 CD34 ϩ cells/kg. Documented infections occurred in 10 but no deaths were recorded. On the other hand, several patients suffered fatigue for a few weeks following the second ASCT, and six patients had lowered performance status during the first 3 months.
Despite these reversible RRT, seven of the 14 patients in CCR returned to their professional activities. The observed CR rate on day 100 of 67% (16/24) seems encouraging in this poor prognosis group. In this series, the 15 patients (NHL ϭ 6; HD ϭ 9) who relapsed after conventional treatment comprised the largest heavily pretreated group of patients. After the first ASCT, 9/15 (NHL ϭ 5; HD ϭ 4) were considered to be in CR, and 3 months after the second ASCT, 10/15 remained in CR (NHL ϭ 3; HD ϭ 7). Thus, this subgroup, comprising patients who stabilized after or responded to the first ASCT, seems to benefit from a second PBSC transplant. With median follow-up at 18 months, 67% (16/23) of patients are alive, and 58% (14/23) are experiencing progression-free survival (9/15 in the NHL group: three patients who had relapsed and six for whom this strategy was the first-line therapy; and 5/9 in the HD group). No conclusions about improvement in survival can be drawn from this limited heterogeneous series. However, the selection of patients was made on the basis of a probability of survival inferior to 40% after one single ASCT.
Several attempts have been made to improve conditioning regimens, but at the present time, none has been evaluated in a randomized study. The consensus, from data available in the literature and through registry analysis, is that little difference, if any, can be detected between the different regimens. 34 To improve upon what can be achieved with one procedure, we used two different preparative chemotherapy regimens so as to exploit the theoretical benefit of any non-cross-resistance between successive treatments and to avoid cumulative toxicity of drugs. The first regimen BCV-Mxt was derived from the classical BCV and was shown to have potential activity in lymphoma. 19 The second regimens were more difficult to define and according to the disease were based on carboplatin-melphalan or aracytine-melphalan in combination with a radiomimetic agent, busulfan. The latter replaced TBI in the second regimen in 13 patients but seemed to contribute towards VOD. 35, 36 VOD led to further reduction of the busulfan dose from 16 to 8 mg/kg. Although two of these three patients had a predisposing factor for VOD, this unusually high rate of hepatic toxicity, in the ASCT setting, should be taken into consideration when defining new experimental regimens for tandem transplants.
The potential benefit of multiple different HDT regimens may include enhancement of cytotoxicity because of the higher doses administered, the repetition of HDT, and the use of non-cross-resistant agents with different mechanisms of action. With the availability of G-CSF mobilized PBPC to enhance hematological recovery, the concept of multiple myeloablative treatments may be effective and more safely studied in chemosensitive tumors. Long-term follow-up of a larger cohort of patients will be needed to ascertain the overall efficacy of this type of therapy and long-term toxicity.
